| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2022 | ‡‡‡ |
|
| 2021 | ‡‡‡ |
|
| 2020 | ‡‡‡ |
|
| 2019 | ‡‡‡ |
|
| 2018 | ‡‡‡ |
|
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Cash | 2.04 | 8.81 | 6.10 | 9.09 |
| Receivables | 5.19 | 4.76 | 4.08 | 6.99 |
| Inventory | 4.14 | 2.20 | 2.07 | 2.61 |
| Other | 3.88 | — | — | — |
| 11.53 | 15.76 | 12.25 | 18.70 |
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Payables | 6.95 | 5.99 | 6.73 | 4.83 |
| ST’ Debt | 25.67 | 10.45 | 10.05 | 17.96 |
| Other | 26.14 | 27.28 | 26.98 | 25.88 |
| 80.81 | 58.13 | 55.92 | 59.61 |
| 10y | 5y | 3y | |
| Sales | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡ | ‡‡‡ |
| Book Value | — | ‡‡‡ | ‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’25 | — | 48.89 | — | — |
100.55
|
| ’24 | — | 50.00 | — | — |
105.11
|
| ’23 | 21.68 | 44.03 | — | — |
96.45
|
| ’22 | 25.35 | 50.55 | 23.48 | 0.19 |
99.58
|
| ’21 | 32.13 | 34.69 | — | — |
100.07
|
| ’20 | 12.85 | 23.60 | 41.43 | 52.76 |
130.64
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’25 | — | — | — | — |
(1.70)
|
| ’24 | — | — | — | — |
11.08
|
| ’23 | — | — | — | — |
10.50
|
| ’22 | — | — | — | (11.16) |
(11.16)
|
| ’21 | 6.70 | 2.32 | — | — |
7.92
|
| ’20 | — | — | — | (0.12) |
(0.12)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’25 | — | — | — | — |
(1.76)
|
| ’24 | — | — | — | — |
6.81
|
| ’23 | — | — | — | — |
2.66
|
| ’22 | — | — | — | (11.41) |
(11.41)
|
| ’21 | 6.70 | 2.32 | — | — |
2.76
|
| ’20 | — | — | — | (6.66) |
(6.66)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’25 | 0.00 | (0.03) | — | — |
(0.06)
|
| ’22 | (0.02) | (0.01) | (0.24) | (0.09) |
(0.41)
|
| ’21 | (0.12) | (1.65) | — | — |
(4.20)
|
| ’20 | (0.51) | (0.39) | (0.12) | (0.54) |
(1.65)
|
| ’19 | — | — | (0.02) | (0.38) |
(0.33)
|
| ’18 | — | — | — | — |
(1.61)
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 1.04 | 0.48 | 0.12 | 0.04 | — | — | — |
Low Price
|
| — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.80 | 1.70 | 0.90 | 0.34 | — | — | — |
High Price
|
| — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1,167 | 1,286 | 1,309 | 1,139 | — | — | — |
Employees
|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.09 | 0.07 | 0.08 | 0.09 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 99.58 | 96.45 | 105.11 | 100.55 | — | — | — |
Revenue
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 53.07% | 47.18% | 44.70% | 46.24% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (13.99) | (7.78) | (0.19) | (3.44) | — | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (14.05%) | (8.07%) | (0.18%) | (3.42%) | — | — | — |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (13.99) | (7.78) | (0.19) | (3.44) | — | — | — |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 9.14 | 9.31 | 9.18 | 8.19 | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 3.65 | 2.20 | 2.20 | 2.10 | — | — | — |
Revenue/Sh
|
| ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | (0.41) | (0.15) | (0.06) | (0.06) | — | — | — |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.41) | 0.24 | 0.23 | (0.04) | — | — | — |
Cash Flow/Sh
|
| ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.01) | (0.18) | (0.09) | 0.00 | — | — | — |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.42) | 0.06 | 0.14 | (0.04) | — | — | — |
Free CF/Sh
|
| ‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.69) | 0.11 | 0.03 | (0.13) | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 27.30 | 43.89 | 47.84 | 47.84 | — | — | — |
Shares
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡ | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
PE Ratio
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.38 | 0.32 | 0.13 | 0.05 | — | — | — |
PS Ratio
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.00 | 6.54 | 10.59 | 31.46 | — | — | — |
PB Ratio
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.66 | 0.40 | 0.21 | 0.09 | — | — | — |
EV/Sales
|
| ‡‡‡ | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.41) | (1.31) | (0.89) | (0.57) | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (11.16) | 10.50 | 11.08 | (1.70) | — | — | — |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.25) | (7.83) | (4.27) | (0.06) | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (11.41) | 2.66 | 6.81 | (1.76) | — | — | — |
FCF
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (69.28) | (42.36) | (43.67) | (40.92) | — | — | — |
Working Cap'
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 30.00 | 14.88 | 11.95 | 20.07 | — | — | — |
Total Debt
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 27.96 | 6.08 | 5.85 | 10.97 | — | — | — |
Net Debt
|
| — | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (18.71) | 4.75 | 1.30 | (6.01) | — | — | — |
Sh' Equity
|
| ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (13.28%) | (6.59%) | (3.78%) | (10.70%) | — | — | — |
ROA
|
| — | ‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (67.90%) | (44.68%) | (16.40%) | (42.40%) | — | — | — |
ROIC
|
| ‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 47.61% | 75.81% | (91.69%) | 314.85% | — | — | — |
ROE
|
Aesthetic Medical International Holdings Group Ltd (PAIYY), a key player in China’s booming aesthetic medical services sector, rode explosive demand for non-invasive treatments to revenue peaks of $131 million in 2020, only to face regulatory crackdowns, COVID disruptions, and profitability erosion that slashed margins from 68% to 45% and triggered massive losses and share dilution. Trading near all-time lows with PS ratios at a screaming 0.13x, PAIYY exemplifies the high-stakes boom-bust in emerging med-beauty markets—yet analyst price targets cluster at levels implying a staggering 107,000% upside, signaling bold bets on a dramatic rebound.
Deleveraging shines through, with debt halved to $12 million and free cash flow turning positive at $6.8 million in 2024, alongside steady employee productivity around $75,000-$80,000 revenue per head. This sets the stage for potential explosive growth if China’s aesthetics regulations ease—as rumored in 2024 tweaks—and consumer sentiment revives, potentially restoring 60% margins and pre-2020 profitability.
This disconnect between battered fundamentals and sky-high targets echoes overhyped winners in regulated growth arenas; monitor Q1 2025 for revenue inflection and margin pops above 50% to unlock transformative upside in this undervalued disruptor.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.